HST Global Reports Termination Of Agreement

HST Global has announced the termination of its Letter of Intent Agreement to purchase Bryomed International.

HST Global looks forward to maintaining the relationship between the parties and will continue to pursue a vendor agreement as Bryomed continues the registration process of its products with the FDA.

Reportedly, HST will also discontinue its efforts to purchase the worldwide rights for the manufacturing and distribution of Salicinium.

Ron Howell, President and CEO of HST Global, said: “With the current economic climate, we will dedicate all of our company resources to the development and expansion of our distribution through our Health and Wellness Centers. Under the guidance of Dr. Forsythe we will continue developing appropriate protocols to address life threatening diseases. At the same time, we expect to accelerate the opening of our proto-type Center in Las Vegas.

In addition, we will mature the expansion and development of our all natural nutritional products designed to address wellness challenges and provide preventative maintenance for overall health. This will allow us to concentrate on products that we control from formulation through to consumer application as well as integrating the educational process necessary to help patients understand the underlying need for good nutrition in achieving and maintaining optimum health,” he added.